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Abstract
Colon cancer is the third most common cancer and the third largest cause of cancer-related death.
Fluorouracil (5-FU) is the front-line chemotherapeutic agent for colon cancer. However, its response rate is
less than 60%, even in combination with other chemotherapeutic agents. The side effects of 5-FU also
limit its application. Nanoparticles have been used to deliver 5-FU, to increase its effectiveness and
reduce side effects. Another common approach for colon cancer treatment is targeted therapy against
the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway. A recently-invented inhibitor of this
pathway, BEZ-235, has been tested in several clinical trials and has shown effectiveness and low side
effects. Thus, it is a very promising drug for colon cancer treatment. The combination of these two drugs,
especially nanoparticle-packed 5-FU and BEZ-235, has not been studied. In the present study, we
demonstrated that nanoparticles of layered double hydroxide (LDH) loaded with 5-FU were more effective
than a free drug at inhibiting colon cancer cell growth, and that a combination treatment with BEZ-235
further increased the sensitivity of colon cancer cells to the treatment of LDH-packed 5-FU (LDH-5-FU).
BEZ-235 alone can decrease colon cancer HCT-116 cell viability to 46% of the control, and the addition of
LDH-5-FU produced a greater effect, reducing cell survival to 8% of the control. Our data indicate that the
combination therapy of nanodelivered 5-FU with a PI3K/Akt inhibitor, BEZ-235, may promise a more
effective approach for colon cancer treatment.
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Abstract: Colon cancer is the third most common cancer and the third largest cause of
cancer-related death. Fluorouracil (5-FU) is the front-line chemotherapeutic agent for colon
cancer. However, its response rate is less than 60%, even in combination with other chemotherapeutic agents. The side effects of 5-FU also limit its application. Nanoparticles have been
used to deliver 5-FU, to increase its effectiveness and reduce side effects. Another common
approach for colon cancer treatment is targeted therapy against the phosphoinositide 3-kinase
(PI3K)/protein kinase B (Akt) pathway. A recently-invented inhibitor of this pathway, BEZ-235,
has been tested in several clinical trials and has shown effectiveness and low side effects. Thus,
it is a very promising drug for colon cancer treatment. The combination of these two drugs,
especially nanoparticle-packed 5-FU and BEZ-235, has not been studied. In the present study,
we demonstrated that nanoparticles of layered double hydroxide (LDH) loaded with 5-FU were more
effective than a free drug at inhibiting colon cancer cell growth, and that a combination treatment
with BEZ-235 further increased the sensitivity of colon cancer cells to the treatment of LDH-packed
5-FU (LDH-5-FU). BEZ-235 alone can decrease colon cancer HCT-116 cell viability to 46% of
the control, and the addition of LDH-5-FU produced a greater effect, reducing cell survival to 8%
of the control. Our data indicate that the combination therapy of nanodelivered 5-FU with a PI3K/
Akt inhibitor, BEZ-235, may promise a more effective approach for colon cancer treatment.
Keywords: layered double hydroxide (LDH), BEZ-235, 5-FU, colon cancer HCT-116 cells,
cell death, apoptosis, PI3K/Akt/mTOR
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Colon cancer is the third most common cancer in humans and has a high mortality
rate. The five-year survival rate for metastatic colon cancer is less than 10%. Many
therapeutic approaches have been used for the treatment of colon cancer, including chemotherapy, radiotherapy, targeted therapy, and immune therapy. Nanoparticles (NPs)
have been used to control drug release. For example, polymer microsphere delivery
allows slower and delayed drug release of valdecoxib, an inhibitor of cyclooxyygenase-2 enzyme.1 Nanodelivery can also avoid the release of drug at pH 1.2–6.8, so
that the drug is not released in the stomach, ensuring colonic release.2 Fluorouracil
is the drug of first choice in chemotherapy for colon cancer. However, its response
rate is less than 60%, even in combination with other chemotherapeutic agents.3 Drug
resistance is a major issue in the clinical application of 5-FU.4 In addition, the severe
side effects of 5-FU limit its clinical application at high dosages. The bioavailability
of 5-FU is poor and its metabolism is rapid. Thus, an effective delivery mechanism for
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5-FU is needed for clinical application.5 In order to increase
the effectiveness of 5-FU and reduce its side effects, several
approaches have been employed, including combinatorial
application with other anticancer agents and the application
of nanotechnology for its delivery.
Recently, several types of NPs have been used to deliver
5-FU to increase treatment efficacy and reduce side effects,
including layered double hydroxide (LDH), liposomes and silicabased NPs.6–9 LDH is an inorganic NP with low toxicity, which
has been used to deliver chemotherapeutic agents, including
5-FU.10–13 Delivery by NPs can increase treatment efficacy and
reduce side effects, as NP-5-FU can accumulate in tumor sites
(due to vascular structural differences between the tumor and
normal tissues). Nanoparticle-loaded drugs can also be taken up
by cells through endocytosis. Therefore, their concentrations in
cells are increased.14 LDH-packed 5-FU has been used together
with curcumin and AllStars Hs Cell Death small interfering
RNAs (siRNAs) to increase treatment efficacy,5,15 but has not
been used with other anticancer agents, such as BEZ-235.
5-FU has been used most often together with oxaliplatin,
to increase patient response to 5-FU.16,17 Furthermore, folic
acid has been included in a treatment regime containing 5-FU
and oxaliplatin. The chemotherapeutic agents irinotecan and
leucovorin have been added to the combinational therapeutic
regime with 5-FU.18,19 In addition, 5-FU has been used in combination with immune therapy and targeted therapies against
B-cell lymphoma 2 (Bcl-2), such as interferon-α, cetuximab,
rapamycin, and siRNA.20–22 A phase III clinical trial showed
that cetuximab significantly increased the effect of 5-FU in
combination with the FOLFIRI regimen.23 Fluorouracil has
also been used with a dual inhibitor of the phosphoinositide
3-kinase (PI3K)/protein kinase B (Akt)/mammalian target
of rapamycin (mTOR) pathway, PI-103.24
PI3K/Akt is a major survival pathway and plays a key
role in many cancers, including colon cancer.25–28 Targeted
therapy against the PI3K/Akt/mTOR pathway has been
extensively studied in colon cancer. The pathway is associated also with resistance to chemotherapeutic drugs.29,30 BEZ235 is a new and very promising inhibitor of the PI3K/Akt
pathway (due to its effectiveness and low side effects). It can
inhibit the activity of both PI3K and mTOR and thus eliminate the feedback activation of PI3K activity due to inhibition
of mTOR. A recent study showed that BEZ-235 is effective
on both PIK3CA-mutated and unmutated colon cancer cell
lines.31 Therefore, BEZ-235 may soon be incorporated into
the present treatment regime for colon cancer. However,
combinational treatment with BEZ-235 and nanoparticledelivered 5-FU, especially the additive or even synergistic
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effect of their treatment, has not been well studied. In the
present study, we investigated the treatment effect of LDHloaded 5-FU and BEZ-235 in the colon cancer cell line
HCT-116. We found that the combination treatment could
dramatically increase cancer cell death, both through cell
cycle changes and apoptotic pathways.

Materials and methods

MgCl2 ⋅6H2O, AlCl3⋅6H2O, NaOH, 5-FU, Tween® 20, protein
lysis buffer, and Triton® 100 were purchased from SigmaAldrich Corp (St Louis, MO, USA). Dulbecco’s Modified
Eagle’s Medium (DMEM), PBS buffer, and Tris buffer were
obtained from Life Technologies Corporation (Mulgrave, Victoria, Australia). BEZ-235 was obtained from Cayman Chemical
Company (Ann Arbor, MI, USA). The Annexin V-FITC Apoptosis detection kit was obtained from BD Biosciences (Franklin
Lakes, NJ, USA). Mouse monoclonal antihuman Bcl-2 antibody
and rabbit antihuman α-tubulin antibody were obtained from
Cell Signaling Technology Inc (Danvers, MA, USA).

Preparation of LDH and LDH-5-FU
LDH was made by a standard method.5,12,13 The 5-FU/Mg2AlLDH hybrid (LDH-5-FU) was synthesized via ion exchange
methods with a hydrothermal treatment. The synthetic procedure involved mixing 0.3 M MgCl2 and 0.1 M AlCl3 solution before quickly adding it to 0.15 M NaOH solution and
stirring for 10 minutes. Then, LDH slurry was collected by
centrifugation. The precipitation was resuspended into 40 mL
of the basic solution containing 0.2 mm of 5-FU (neutralized with dilute NaOH solution, with pH 8–9) for 1 hour.
After washing two times, the LDH-5-FU was resuspended
in 40 mL of distilled water and transferred to an autoclave
(stainless steel with a teflon lining) and incubated at 100°C
for 16 hours. After hydrothermal treatment, a transparent,
homogeneous suspension of LDH-5FU was obtained.

Physicochemical characterization
The hydrodynamic particle size and the zeta potential of
the LDH and LDH-5-FU nanohybrids were determined by
dynamic light scattering (DLS). All measurements were carried out at 25°C with photon correlation spectroscopy using a
Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, UK).
Each parameter was measured in triplicate and the average
value was calculated. Transmission electron microscopy
(TEM) images were obtained using a JEM-1010A
(JEOL, Tokyo, Japan) at an acceleration voltage of 100 kV.
The loading amount of 5-FU into LDH was determined by
ultraviolet-visible absorbance (UV-Vis) at 265 nm.
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Cell lines and cell viability test: MTT assay
The colon cancer HCT-116 cell line was purchased from
American Type Culture Collection (ATCC®) (Manassas, VA,
USA) and the cells were maintained in complete DMEM,
supplemented with 10% fetal calf serum, 1% penicillin,
and 1% streptomycin, in 75 mL flasks at 37°C and 5%
CO2. For the cytotoxicity assay, cells were trypsinized for
5 minutes and resuspended in a medium to dilute the concentration to 1×105/mL. Then 100 µL of cells was added to
each well in a 96-well plate for the cytotoxicity assay, under
treatments of various concentrations of BEZ-235 and LDH5-FU. An MTT assay was used to measure cell viability,
according to the manufacturer’s (Sigma-Aldrich, St louis;
MO) instructions.

Cell cycle analysis
Propidium iodide (PI) was used to stain the DNA content.
HCT-116 cells were harvested by trypinization and were
washed with phosphate buffered saline (PBS). The cells
were resuspended in PBS at 2×106/mL. With 1 mL of the
resuspended cells, 1 mL of 100% cold ethanol was added
dropwise and vortexed gently. The mixture was stored overnight at -20°C. After washing the cells with cold PBS, they
were resuspended in a 300 µL PI/Triton buffer containing
0.01% Triton 100 (by volume) and 6 µg PI. After incubation
at room temperature for 40 minutes, the stained cells were
analyzed with flow cytometry (Accuri™, BD Biosciences,
Franklin Lakes, NJ, USA) and (FlowJo software, Tree Star
Inc, Ashland, OR, USA).

Cell apoptosis analysis
Cell apoptosis and cell death were detected using the Annexin
V apoptosis kit, following the procedure recommended by
the manufacturer (BD; Bioscienes, Franklin Lakes, NJ,
USA). HCT-116 cells were cultured in a 6-well plate with
2×105 cells in each well. Cells were treated for 24 hours with
various concentrations of BEZ-235 ranging from 25–400 nm,
and LDH-5-FU from 3–12 µg/mL. As well, a combinational
treatment of BEZ-235 and LDH-5-FU was used. Treated cells
were collected by centrifugation and suspended in 100 µL
of the provided buffer and stained with Annexin V-FITC
conjugates and PI for 15 minutes. Cell death and apoptosis
were then detected by flow cytometry.

Data analysis
Data collected from each group (experimental and control)
were expressed as mean ± standard deviation. The one-way
ANOVA and unpaired Student’s t-test (Prism version 6,
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GraphPad Software Inc, La Jolla, CA, USA) were used to
analyze the differences between groups and discriminate the
significant differences between experimental and control
groups (one-way ANOVA: P0.05).

Results
Characterization of LDH and LDH-5-FU
As shown in Figure 1A, the synthesized LDH suspension
had platelike particles with a hexagonal shape. The DLS
data in Figures 1C and 1D indicated that the average size
of LDH nanoparticles was ~109 nm with a zeta potential of
+42.9 mV, consistent with our previous reports.15 After loading 5-FU into LDH nanoparticles, LDH-5-FU nanohybrids
presented a narrow particle size distribution in the range of
50–150 nm and a zeta potential of +40.6 mV (Figures 1C and
1D). Compared with LDH, the average size of LDH-5-FU
decreased from 109 nm to 85 nm, as reported previously,15
due to inhibition of the hydroxide layer growth by the anionic
5-FU. The TEM image in Figure 1B shows that the LDH5-FU nanohybrid had a similar platelike morphology to the
LDH nanoparticle. The amount of 5-FU loaded in LDH
nanoparticles was 9.6% by weight, determined by UV-Vis.

Cytotoxicity induced by 5-FU,
LDH-5-FU, and BEZ-235
We compared the cytotoxicity of LDH-5-FU with free
5-FU on the colon cancer cell line HCT-116. In Figure 2A,
it can be seen that both 5-FU and LDH-5-FU produced a
dose-dependent cytotoxic effect on HCT-116 cells after
24 hour treatment. LDH-5-FU has much higher cytotoxicity than free 5-FU. It started to show the effect at 3 µg/mL,
with an increased effect at 6 µg/mL, and the number of
surviving cells decreased to about 20% at 12 µg/mL. The
half maximal inhibitory concentration (IC50) for the inhibitory effect of LDH-5-FU on HCT-116 is 5.585 µg/mL.
The free 5-FU had much lower cytotoxicity and it only
reduced cell viability to 56%, even at 48 µg/mL. We chose
6 µg/mL for the study because of its combinatorial effect
with BEZ-235.
In order to select a dose of BEZ-235 to test the effect
of combination treatment of LDH-5-FU and BEZ-235, the
effect of BEZ-235 on HCT-116 cells was tested at different doses. After 24 hour incubation, BEZ-235 produced
dose-dependent cytotoxicity on HCT-116 cells in the dose
range from 50–400 nm (Figure 2B). IC50 for the inhibitory effect of BEZ-235 on HCT-116 cells is 78.2 nm. We
chose the concentration of 100 nm for the combination
treatment.
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Figure 1 Featured structure of LDH and LDH-5-FU nanohybrids.
Notes: (A–B) Tranmission electron microscopy images of LDH and LDH-5-FU. The scale bar represents 200 nm. (C) Particle size distribution of LDH and LDH-5-FU from
dynamic light scattering. (D) Zeta potential of LDH and LDH-5-FU.
Abbreviations: LDH, layered double hydroxide; 5-FU, fluorouracil.
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Figure 2 Dose-dependent effect of 5-FU, LDH-5-FU, and BEZ-235 on HCT-116 cells.
Notes: A shows both 5-FU and LDH-5-FU produced cytotocitiy on HCT-116 cells at various concentrations. The effect of LDH-5-FU is much stronger than that of 5-FU
alone. B shows BEZ-235 produced dose-dependent cytotoxic effect on HCT-116 cells in the concentration range from 25 nm to 400 nm. *** indicates P0.001; n=3.
Abbreviations: LDH, layered double hydroxide; 5-FU, fluorouracil.
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More effective inhibition by the
combination of LDH-5-FU and BEZ-235
Figure 3 showed that LDH-5-FU and BEZ-235 together
produced a higher cytotoxic effect. It is shown that both LDH5-FU and BEZ-235 alone produced a middle range of cytotoxicity to HCT-116 cells. Treatment with BEZ-235 alone
at 100 nm decreased cell survival to 46% of the control.
Treatment with LDH-5-FU at 6 µg/mL alone decreased the
survival rate to 56%. However, the combination use of the
two drugs resulted in massive cell death, reducing survival
rate to 8% of the control. The cell survival rate was significantly lower than both LDH-5-FU and BEZ-235 treatments
alone. Therefore, BEZ-235 increases the sensitivity of
HCT-116 to LDH-5-FU treatment. These data clearly show
that a combination treatment with BEZ-235 and LDH-5-FU
remarkably suppresses HCT-116 cell growth.

Combination treatment of LDH-5-FU
and BEZ-235 caused more G1 arrest

Cell viability (%)

It was reported that BEZ-235 could induce cell cycle G1
arrest in the prostate cancer cell line PC3M.32 To examine
whether combination treatment with LDH-5-FU and BEZ235 has the same effect, we carried out a cell cycle analysis.
The result showed that the combination treatment remarkably increased the Sub-G1 (apoptotic) population (51.85%)
(Figure 4), compared with single drug treatments (16.75%
and 23.05%, for LDH-5-FU and BEZ-235, respectively)
and the untreated control (Figure 4). Instead of G1 arrest,

we observed a remarkable decrease in the G1 phase and an
increase of population at the G2/Mitotic (G2/M) phase after
the combination treatment (Figure 4).

LDH-5-FU and BEZ-235 caused cell
death and apoptosis
We further assayed the combination treatment effect of
LDH-5-FU and BEZ-235 on cell death using the Annexin
V apoptosis kit. As shown in Figure 5, both LDH-5-FU and
BEZ-235 produced cell death and apoptosis after 24 hour
treatment. LDH-5-FU alone, at 6 µg/mL, resulted in 28%
cell apoptosis and death. Treatment with BEZ-235 alone, at
100 nm, led to 9% cell apoptosis and cell death. However, the
combinatorial application of both agents produced a greater
effect, resulting in 46% cell apoptosis and death. Compared
with the control, the LDH-5-FU treatment caused some early
apoptosis (10.76% versus 1.09%) (Figures 5A and 5B) and
this effect was carried on into the combination treatment
(10.68%) (Figure 5C). BEZ-235 treatment alone did not
induce much early apoptosis (Figure 5D). In addition, LDH5-FU (Figure 5B) and combination treatments (Figure 5C)
caused much more necrotic cell death (right upper quarters) than either BEZ-235 alone (Figure 5D) or the control
(Figure 5A). We further analyzed Bcl-2 protein levels (an
antiapoptotic protein associated with mitochondria apoptosis
pathways) and found that treatment with a single drug led to
the reduction of this protein. The most significant reduction
was seen in the combination treatment (Figure 5E), which
is consistent with the above results.

Discussion
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Figure 3 Combination treatment of BEZ-235 and LDH-5-FU to HCT-116 cells.
Notes: The MTT assay result shows that the combinational treatment with BEZ235 at 100 nm and LDH-5-FU at 6 µg/mL is much more effective at reducing cancer
cell viability than any treatments with a single drug.
Abbreviations: LDH, layered double hydroxide; 5-FU, fluorouracil.
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Fluorouracil is a common chemotherapeutic agent used
in the treatment of colon cancer. It is a suicide inhibitor
of thymidylate synthase, an enzyme necessary for DNA
replication.33,34 Fluorouracil is very toxic to normal cells and
causes severe side effects at the therapeutic dosage, including damage to bone marrow, the gastrointestinal tract, and
skin.35,36 To reduce side effects, its dose must be decreased
through combinational application with other drugs or drug
delivery systems. In this study, we used LDH to lower the
dose of 5-FU, at which higher cytotoxicity to cancer cells
still remained. We also tested the combination treatment of
LDH-loaded 5-FU with BEZ-235.
Nanoparticles have been extensively used for drug delivery,
to increase drug efficacy and reduce side effects. In our study,
we showed that nanodelivered 5-FU increased cytotoxicity to
HCT-116 markedly. This may be due to the endocytosis effect.
In this process, LDH-5-FU is engulfed by HCT-116 cells as
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Abbreviations: LDH, layered double hydroxide; 5-FU, fluorouracil; PI, propidium iodide.
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a particle, which contains more 5-FU molecules than free
5-FU.37 This process facilitates entry of 5-FU into cells and
therefore results in higher cytotoxicity. So far, LDH-5-FU has
only been tested with curcumin as a combinational treatment
on cancer cells, where LDH-5-FU has been shown to have a
synergistic effect with solid lipid nanoparticle-curcumin.5 In
our study, we tested the effect of LDH-5-FU on HCT-116 cells
in combination with BEZ-235, a newly-invented PI3K/Akt
inhibitor for colon cancer treatment.
The rationale behind applying 5-FU and a PI3K/Akt
inhibitor is based on the effectiveness of inhibition of the
pathway in colon cancer treatment.38–40 We have shown that
activation of the PI3K/Akt pathway can reduce the effect of
chemotherapeutic agents, including 5-FU, on colon cancer
cell lines.41,42 Inhibition of the pathway increased the sensitivity of HT-29 cells to 5-FU. Leptin has also been shown
to increase colon cancer resistance to 5-FU treatment, via
activation of the PI3K/Akt pathway.43 Chen et al showed
that siRNA knockdown of focal adhesion kinase (FAK)
reduced Akt activity and increased colon cancer sensitivity to
5-FU.44 Recently, Liao et al showed that regular use of aspirin
increased the survival time of colorectal cancer patients with
the mutated PIK3CA gene but not of those with the wild-type
PIK3CA.45 The effectiveness of BEZ-235 has been extensively
tested in PIK3CA-mutated colon cancer cell lines.31 Therefore,
it is useful for the combination study with LDH-5-FU.
Our study shows for the first time that the dual inhibitor
of the PI3K/Akt/mTOR pathway, BEZ-235, can sensitize
HCT-116 cells to LDH loaded with 5-FU. This is a novel
approach for the treatment of colon cancer. HCT-116 cells
have a mutation in PIK3CA. Therefore, their PI3K pathway
is highly-activated and thus is sensitive to inhibition of the
pathway. BEZ-235 has been used for several clinical trials
in colon cancer treatment. The approach we tested could be
applicable for clinical trials, as both BEZ-235 and 5-FU are
approved for clinical use as anticancer agents. BEZ-235 is
known to have minor side effects. Several studies showed
that it is well-tolerated in clinical trials. 5-FU is a traditional
therapy drug for colon cancer. LDH is also a low toxicity
nanoparticle. In our study, the concentration of 5-FU is
300 µg/mL and the concentration of LDH is 4 mg/mL. At
the concentration of 6 µg/mL of 5-FU, the concentration of
LDH is 80 µg/mL. At this concentration of LDH, it has no
toxicity to normal cells.
Muller et al studied the effect of BEZ-235 and irinotecan
on HT-29 cells and showed that BEZ-235 increased the
effect of irinotecan.46 This study indicated that inhibition
of the PI3K/Akt/mTOR pathway can be combined with a
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c hemotherapeutic agent to increase treatment efficacy in
colon cancer. However, only irinotecan was tested. 5-FU
and other chemotherapeutic agents commonly used in colon
cancer treatment were not tested.
A dual inhibitor of the PI3K/Akt/mTOR pathway, PI-103,
has been shown to increase the efficacy of 5-FU in both in
vitro and in vivo studies in gastric cancer.24 In comparison
with single inhibitors of PI3K and mTOR, PI-103 produced
an enhanced effect. PI-103 is the first-identified dual inhibitor
of the PI3K and mTOR pathways. Although it has a strong
antitumor effect, it is not suitable for clinical application, due to its high toxicity.47,48 In contrast, BEZ-235 has
been extensively tested in clinical trials for many types of
cancers, and has demonstrated high effectiveness and low
toxicity.39,40,49–52 In the present study, we applied BEZ-235 in
colon cancer HCT-116 in combination with LDH-5-FU to
demonstrate their combination effect.
Our study has partially elucidated the mechanisms for
the combination effect of BEZ-235 and LDH-5-FU. In cell
cycle analysis, the combination treatment produced many
more sub-G1 apoptotic cells than BEZ-235 or LDH-5-FU
alone, indicating the additive effect on cell death of the two
drugs. Cell cycle arrest was observed in the G2/M phase,
with a remarkable decrease of the G1 phase. This differs from
another study, which showed that BEZ-235 caused G1 arrest
in PC3M cells.32 The difference could be caused by the different cell types and drug doses used. In that study, 10 nm and
50 nm of BEZ-235 were used. The combination treatment
produced more reduction in Bcl-2. Bcl-2 is an antiapoptotic
protein and its reduction could lead to increased apoptosis.
Therefore, both cell proliferation and cell apoptosis are
affected by the combination treatment. Further studies are
warranted, so that the combination application can be used
for clinical trials.
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